Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Literature
1.
Brandão RD, van Roozendaal K, Tserpelis D, García EG, Blok MJ (2011) Characterisation of unclassified variants in the BRCA1/2 genes with a putative effect on splicing. Breast Cancer Res Treat 129(3):971–982. doi:10.​1007/​s10549-011-1599-7 PubMedCrossRef
2.
Burn TC, Connors TD, Klinger KW, Landes GM (1995) Increased exon-trapping efficiency through modifications to the pSPL3 splicing vector. Gene 161(2):183–187PubMedCrossRef
3.
4.
Whiley P, Pettigrew C, Brewster B, Walker L, Investigators k, Spurdle A, Brown M (2010) Effect of BRCA2 sequence variants predicted to disrupt exonic splice enhancers on BRCA2 transcripts. BMC Med Genet 11(1):80. doi:10.​1186/​1471-2350-11-80 PubMedCrossRef
5.
Hansen T, Steffensen A, Jønson L, Andersen M, Ejlertsen B, Nielsen F (2010) The silent mutation nucleotide 744 G→A, Lys172Lys, in exon 6 of BRCA2 results in exon skipping. Breast Cancer Res Treat 119(3):547–550. doi:10.​1007/​s10549-009-0359-4 PubMedCrossRef
Metadata
Title
BRCA1 c.4987-3C>G is a pathogenic mutation
Authors
Rita D. Brandão
Kees E. P. van Roozendaal
Demis Tserpelis
Beppy Caanen
Encarna Gómez García
Marinus J. Blok
Publication date
01-01-2012
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2012
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-011-1878-3

Other articles of this Issue 2/2012

Breast Cancer Research and Treatment 2/2012 Go to the issue

Epidemiology

Head-to-head comparison of the 70-gene signature versus the 21-gene assay: cost-effectiveness and the effect of compliance

Epidemiology

Measurement properties of the English and Chinese versions of the Functional Assessment of Cancer Therapy—Breast (FACT-B) in Asian breast cancer patients

Erratum

Erratum to: Evaluation of variants in the CHEK2, BRIP1 and PALB2 genes in an Irish breast cancer cohort

Brief Report

The CIRAS study: a case control study to define the clinical, immunologic, and radiographic features of aromatase inhibitor-induced musculoskeletal symptoms

Epidemiology

Changes in perceived attentional function in women following breast cancer surgery

Preclinical study

The effect of mTOR inhibition alone or combined with MEK inhibitors on brain metastasis: an in vivo analysis in triple-negative breast cancer models
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits